Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial.

Vogl, Thomas J.; Lee, C.; Lencioni, Riccardo; Malagari, K.; Pilleul, F.; Denys, Alban; Watkinson, A.; Lämmer, Johannes

doi:10.1200/jco.2010.28.15_suppl.e14660

Cited by 25 publications

(46 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the 19 % occurrence of grade 3 or higher AEs compares favorably to the 29.6 % incidence of serious AEs (defined as events resulting in death; immediately life-threatening; resulting in permanent/significant disability/incapacity; requiring or extending inpatient hospitalization; congenital anomaly/birth defects) reported in the PRECISION V trial [18] with doxorubicin lipiodol TACE. In another article reporting on the same trial [19], the overall incidence of the postembolization syndrome was higher than that reported here (72 % vs. 30.9 %). In our study, serum levels of AST, ALT, and bilirubin returned to baseline levels after 1 month, as reported in the PRECISION V study [19].…”

Section: Discussioncontrasting

confidence: 39%

Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

Favelier

Boulin

Hamza

et al. 2012

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Background There is still no consensus about the best chemotherapeutic agent for transarterial chemoembolization (TACE). A recent in vitro study demonstrated that idarubicin, an anthracycline, was by far the most cytotoxic drug on human hepatocellular carcinoma (HCC) cell lines. Idarubicin is much more lipophilic than doxorubicin, leading to higher cell penetration through lipidic membranes and greater accumulation of the drug in the lipiodol. Furthermore, idarubicin has the ability to overcome multidrug resistance. Therefore, we designed this pilot human study to evaluate the safety and efficacy of lipiodol TACE using idarubicin. Methods In 21 consecutive patients treated by lipiodol TACE with idarubicin (10 mg) for HCC, safety data, tumor response (Response Evaluation Criteria in Solid Tumors, mRECIST), time to treatment failure (TTTF), and overall survival were evaluated. Results Postembolization syndrome was observed after 30.9 % (17 of 55) of sessions. No patient died from a TACE-related complication. No hematological grade 3-5 adverse event was observed. At least one grade 3 or higher adverse event occurred in 19 % (4 of 21) of patients. On imaging, no progression was encountered; four patients (24 %) exhibited stable disease, 12 (57 %) exhibited a partial response, and five (19 %) exhibited a complete response. Median TTTF was 16.7 months (Kaplan-Meier analysis). At 6 months, 94.7 % (95 % confidence interval [CI] 68.1-99.2) of patients did not reach treatment failure, whereas treatment failure was not reached in 50.6 % (95 % CI 21.6-73.9) of patients at 1 year. Overall survival was 83.5 % (95 % CI 57-94.4) at 1 year. Conclusion Idarubicin seems safe and effective in lipiodol TACE of HCC. This warrants further study to determine the potential of this drug to replace doxorubicin for TACE.

show abstract

Section: Discussioncontrasting

confidence: 39%

Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

Favelier

Boulin

Hamza

et al. 2012

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

“…Klinikinėje praktikoje plačiausiai taikomos TACE ir DEB TACE technikos, kurios laikomos lygiavertėmis vertinant bendrą išgyvenamumą ir sunkias nepageidaujamas reakcijas [7,9,10,11].…”

Section: įVadasunclassified

“…Ilgalaikį ir pastovų vietišką citotoksinį efektą padeda užtikrinti palaipsninis doksorubicino atpalaidavimas [13]. DEB TACE procedūros metu, palyginti su TACE, sumažėja chemoterapinio preparato patekimas į bendrą kraujotaką ir sisteminis šalutinis poveikis (alopecija, mielosupresija) [7,9,10,14].…”

Section: įVadasunclassified

See 1 more Smart Citation

Hepatoceliulinės Karcinomos Gydymo Transarterine Chemoembolizacija Doksorubicinu Impregnuotomis Mikrosferomis (Deb Tace) Lietuvos Sveikatos Mokslų Universiteto Ligoninėje Kauno Klinikose Analizė

Pranculis

Kievišas

Kievišienė

et al. 2015

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

SANTRAUKAReikšminiai žodžiai: transarterinė chemoembolizacija (TACE), transarterinė chemoembolizacija doksorubicinu impregnuotomis mikrosferomis (DEB TACE), hepatoceliulinė karcinoma (HCC). Hepatoceliulinė karcinoma (HCC) -dažniausias pirminis kepenų navikas. Kepenų rezekcija, transplantacija arba radiodaž-ninė abliacija galimos tik kai yra labai ankstyvos arba ankstyvos vėžio stadijos. Transarterinė chemoembolizacija (TACE) yra pirmo pasirinkimo gydymo metodas daugiažidininiu kepenų vėžiu sergantiems pacientams. Tikslas. Išanalizuoti transarterinės chemoembolizacijos doksorubicinu impregnuotomis mikrosferomis (DEB TACE) būdu dėl hepatoceliulinės karcinomos gydytų pacientų gydymo išeitis Lietuvos sveikatos mokslų universiteto ligoninėje Kauno klinikose (LSMUL KK).Tyrimo medžiaga ir metodai. Atliktas retrospektyvinis tyrimas, įtraukta 20 HCC sergančių ir DEB TACE gydytų pacientų. Visiems pacientams nuo 2012 m. birželio mėn. iki 2015 m. kovo mėn. LSMUL KK atliktos superselektyvios DEB TACE procedūros naudojant doksorubicinu impregnuotas "Embozene TANDEM®" ("CeloNova", "BioScience", San Antonijus, JAV) mikrosferas. Gydymo išeitims vertinti analizuotas pacientų išgyvenamumas (mediana ir bendras išgyvenamumas), radiologinis atsakas į gydymą ir a-fetoproteino (AFP) koncentracijos pokytis lyginant reikšmes prieš pirmąjį DEB TACE ciklą ir po jo. Radiologiniam atsakui vertinti taikyti modifikuoti solidinių navikų atsako į gydymą vertinimo kriterijai (mRECIST). Išgyvenamumas vertintas taikant Kaplano ir Mejerio (Kaplan-Meier) metodą. Rezultatai. Išgyvenamumo mediana nuo diagnozės datos ir nuo pirmosios DEB TACE buvo atitinkamai 31,5 ± 9 mėn. ir 19,5 ± 3,9 mėn., bendras išgyvenamumas po 6 mėn. -100 proc. ir 93,3 proc., po 1 m. -80 proc. ir 79 proc., po 2 m. -56,1 proc. ir 29,6 proc. Objektyvus radiologinis atsakas po 1 ir 3 mėn. pasiektas atitinkamai 78,6 proc. ir 77,8 proc. AFP kon-

show abstract

“…8 Clinical studies have shown that DEB loaded with doxorubicin has a safe pharmacokinetic profile with lower systemic drug exposure and significantly reduced liver toxicity compared with conventional TACE. [9][10][11] Despite these advances and technical refinements, the long-term survival of patients managed with TACE are not fully satisfactory, mainly as a result of the high rates of tumor recurrence. TACE exerts therapeutic effects only in the treated territory; thus other HCC undetected at the time of the procedure may progress or new tumors may develop.…”

Section: Introductionmentioning

confidence: 99%

Chemoembolization for Hepatocellular Carcinoma

2010

High-Yield Imaging: Interventional

View full text Add to dashboard Cite

Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial.

Cited by 25 publications

References 0 publications

Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

Hepatoceliulinės Karcinomos Gydymo Transarterine Chemoembolizacija Doksorubicinu Impregnuotomis Mikrosferomis (Deb Tace) Lietuvos Sveikatos Mokslų Universiteto Ligoninėje Kauno Klinikose Analizė

Chemoembolization for Hepatocellular Carcinoma

Contact Info

Product

Resources

About